| 1 |
Evolving utility of apremilast in dermatological disorders for off-label indications |
|
|
| Hitaishi Mehta, Apoorva Sharma, Sunil Dogra |
|
| Clinical and Experimental Dermatology. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors |
|
|
| Aditya K. Gupta, Tong Wang, Shruthi Polla Ravi, Mary A. Bamimore, Vincent Piguet, Antonella Tosti |
|
| Journal of the European Academy of Dermatology and Venereology. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options |
|
|
| A. Sterkens, J. Lambert, A. Bervoets |
|
| Clinical and Experimental Medicine. 2021; 21(2): 215 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast |
|
|
| Eleftherios Ntouniadakis, Fredrik Landström |
|
| Case Reports in Dermatology. 2020; 12(3): 275 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Development of alopecia areata during phosphodiesterase 4 inhibitor treatment for psoriasis: A case report |
|
|
| Chen Peng, Jiajing Lu, Xuemei Yi, Yangfeng Ding, Yunlu Gao, Wenjuan Chen |
|
| Dermatologic Therapy. 2020; 33(6) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors? |
|
|
| A. Abdelmaksoud, M. Goldust |
|
| Journal of the European Academy of Dermatology and Venereology. 2020; 34(11) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
